

New Products - Tafinlar

Tafinlar (**dabrafenib mesilate**) is an ATP-competitive inhibitor of certain RAF kinases (BRAFV600E, BRAFV600K). Tafinlar is indicated for the treatment of patients with BRAF V600 mutation positive unresectable stage III or metastatic (stage IV) melanoma. Confirmation of BRAF V600 mutation using an approved/ validated test is required for selection of patients appropriate for Tafinlar therapy. Tafinlar is available as 50 and 75 mg capsules in bottles of 120's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.